Takeda Pharmaceutical will discontinue GAMMAGARD S/D by December 31, 2027, the company announced, with existing inventory to remain available until stocks expire or deplete in 2028.
The immunoglobulin therapy has treated primary immunodeficiency disorders for decades. Takeda cited portfolio optimization as the driver behind the phase-out decision.
GAMMAGARD S/D competes in a crowded immunoglobulin market dominated by CSL Behring, Grifols, and Octapharma. The global immune globulin market reached $12.8 billion in 2023, growing at 6.2% annually as demand rises for rare disease treatments.
Takeda's move follows a broader trend of pharma companies exiting legacy products to focus on higher-margin therapies. The company has invested heavily in rare disease and oncology pipelines, acquiring Shire Pharmaceuticals for $62 billion in 2019 to expand its immunology portfolio.
Investors reacted neutrally to the announcement, viewing it as a minor portfolio adjustment rather than a material revenue impact. GAMMAGARD S/D represents a small fraction of Takeda's $30.4 billion annual revenue, with newer immunoglobulin products like CUVITRU and HYQVIA driving growth in the segment.
Patients currently on GAMMAGARD S/D therapy will need to transition to alternative treatments before the 2028 depletion deadline. Physicians typically require 6-12 months to safely switch immunoglobulin therapies, giving adequate time for migration.
Takeda faces pricing pressure across its immunoglobulin line as insurers push back on therapy costs exceeding $100,000 annually per patient. Biosimilar competition remains limited in this category due to complex manufacturing processes.
The discontinuation aligns with Takeda's 2024 strategic plan to streamline operations and divest non-core assets. The company sold its over-the-counter portfolio and diabetes drug pipeline to concentrate on rare diseases, gastroenterology, and plasma-derived therapies.
Market analysts expect minimal impact on Takeda's share price, with attention focused on the company's pipeline drugs in inflammatory bowel disease and hemophilia. The stock trades at 13.2x forward earnings, below the pharma sector average of 15.8x.